Resumen de: WO2025177045A1
The present invention relates to a fusion protein, nanoparticles composed of a plurality of monomers of said fusion protein, nucleic acids encoding said fusion protein, and therapeutic applications thereof. In particular, the fusion protein comprises a first domain based on human ferritin and a second domain conjugated to said first domain and located N-terminally with respect to said first domain, which second domain comprises at least one amino acid sequence of a programmed cell death ligand-1 (PD-L1) binding peptide and/or at least one amino acid sequence of a tumor-penetrating peptide.
Resumen de: CN122849484A
本发明公开了一种仿生纳米酶及制备方法与应用,一种仿生纳米酶,是以铜/锌双金属沸石咪唑骨架为核心,包覆有聚多巴胺的纳米颗粒,所述铜/锌双金属沸石咪唑骨架简称CZ‑MOF。实验证明,本发明的一种仿生纳米酶能有效清除处于氧化应激状态下的NCM‑460细胞的ROS;能有效抑制炎症性巨噬细胞并促进其向抗炎M2表型极化;能抑制Th17细胞活化、同时促进调节性T细胞(Treg)应答发挥抗炎作用;能促进纳米颗粒在IBD病灶带正电荷的结肠部位靶向富集,从而提升治疗效果。本发明的仿生纳米酶体系稳定,生物相容性良好。本发明的制备方法简单便捷,在制备治疗溃疡性结肠炎药物中的应用。
Resumen de: WO2025147528A1
The present invention is based on the surprising discovery that a lipid nanoparticle (LNP) bearing sialic acid residues on the surface can withstand nebulization and maintain its integrity. The invention provides an LNP composition comprising a lipid bearing, or substituted by, a sialic acid (SA) residue such as a ganglioside, a ganglioside derivative, a mimetic, a SA-bearing entity or a combination thereof. The lipid nanoparticles described herein can incorporate nucleic acid molecules, or cargos, withstanding nebulization, and delivering the cargos to the lung via a nebulization-mediated delivery. The present invention also provides methods of using the LNP compositions described herein for pharmaceutical applications. For example, the LNPs provided herein are useful for the treatment of various pulmonary diseases. The LNPs provided herein are also useful for prophylactic applications including vaccines for infectious diseases, allergies, autoimmune diseases and cancer.
Resumen de: CN121910693A
The invention relates to a preparation method of pH and GSH dual-response cyclodextrin nanoparticles. The preparation method comprises the following steps: S1, preparing a 10mg/mL lecithin absolute ethyl alcohol solution; s2, a DSPE-PEG 2000-UM206 solution with the concentration of 9 mg/mL is prepared; s3, preparing a water phase; s4, preparing an organic phase; and S5, nano-precipitate self-assembly: in a round-bottom flask, rapidly magnetically stirring the water phase at room temperature, dropwise adding the organic phase into the water phase at a speed of less than 1 mL per minute, and stirring at room temperature for 2 hours. And S6, purification of the nanoparticles: transferring the solution into a 30 kDa ultrafiltration tube, centrifuging for 20 minutes at 4000 * g, and cleaning with PBS for 3 times to obtain the acetalated disulfide bond beta-cyclodextrin dimer nanoparticles. When the pH and GSH double-response cyclodextrin nanoparticle prepared by the preparation method of the pH and GSH double-response cyclodextrin nanoparticle is used for delivering HHT, the pH and GSH double-response cyclodextrin nanoparticle has a sensitive pH/GSH double-response function and an efficient tumor killing effect, has a good treatment effect on OCSCs, can give full play to the tumor killing effect of the HHT, and also can effectively reduce the drug side effect of the HHT.
Resumen de: WO2019204869A1
The present invention relates to improved prodrugs, and compositions thereof. In particular, it relates to amphiphilic gemcitabine prodrugs or amphiphilic prodrugs of other biologically active molecules with the capacity to make liquid crystalline nanostructured nanoparticles, and uses thereof to treat animals, including humans.
Resumen de: CN113636947A
Compounds are provided having the following structure: (I) or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, L1, L2, G1, G2 and G3 are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.
Resumen de: WO2025098967A1
The present invention provides a complex for use in delivering a cargo across a mucus barrier, the complex comprising a particle with a surface coated with catalase; and the cargo, wherein the catalase is attached over the whole surface of the particle. The invention also provides a pharmaceutical composition comprising the complex, and the complex or the pharmaceutical composition for use in a therapeutic, prophylactic, and/or diagnostic method.
Resumen de: WO2025096940A1
The present invention relates to lipids that include novel triazole, and alkyl- and alkene-substituted amine compounds, intermediates in their synthesis, and uses of such triazole, and alkyl- and alkene-substituted amine compounds in, for example, lipid nanoparticle compositions for drug delivery and cancer treatments.
Resumen de: CN122849277A
本发明公开了一种靶向tRF‑Glu‑TTC‑009的核酸抑制剂在制备改善肿瘤免疫微环境药物中的应用,属于生物医药技术领域。本发明提供的核酸抑制剂(包括反义寡核苷酸、siRNA、shRNA或antagomir)通过特异性封闭tRF‑Glu‑TTC‑009,解除其对TAB1/IRAK4的靶向抑制,恢复NF‑κB信号活性,从而将巨噬细胞由M2样表型逆转为M1样抗肿瘤表型,并重塑肿瘤免疫微环境。对乳腺癌的临床治疗具有重要意义。
Resumen de: CN122849470A
本申请属于生物医用材料技术领域,具体涉及一种载有尿酸酶的自润滑纳米材料及其制备方法。所述载有尿酸酶的自润滑纳米材料包括主体材料和负载于主体材料上的药物分子;所述主体材料包括多巴胺甲基丙烯酰胺、含冠醚配位基团的可聚合丙烯酸酯类功能单体和2‑甲基丙烯基酰氧乙基磷酰胆碱。本申请所述载有尿酸酶的自润滑纳米材料将润滑材料、钠离子络合结构和尿酸酶递送功能集于同一自组装纳米颗粒体系中。相比于传统治疗方案,本申请所述材料可通过关节腔局部注射直接作用于痛风病灶区域,有利于提高局部有效浓度,减少全身给药带来的潜在副作用,并更好地适应痛风性关节炎中尿酸盐晶体沉积、炎症反应和润滑丧失并存的复杂病理环境。
Resumen de: CN122849191A
本发明涉及生物材料技术领域,特别是涉及一种表面生长无机钙壳层的锰基金属有机框架药物载体及其制备方法和抗肿瘤应用。本发明利用无机钙壳层提升载体体内安全性与肿瘤靶向能力,稳定优化药物体内药代动力学特征,实现化疗药物与功能性锰离子安全长效共递送。载体富集至肿瘤微环境后,可依托酸性微环境特异性逐层降解释药,同步介导化学动力学治疗、激活机体内源抗肿瘤免疫通路,多元联动实现高效协同抑瘤。最终确立一类生物相容性佳、活体安全性高的新型肿瘤协同锰疗法。
Resumen de: CN122849190A
本申请实施例提供了一种黄芩苷靶向纳米粒及其制备方法和用途,涉及生物医药技术领域。本申请实施例的黄芩苷靶向纳米粒包括聚乳酸‑羟基乙酸共聚物基质和脂质组合物,所述聚乳酸‑羟基乙酸共聚物基质中分散包埋有黄芩苷和油酸修饰超顺磁性四氧化三铁纳米粒;所述脂质组合物分布于聚乳酸‑羟基乙酸共聚物基质的表面;所述脂质组合物包括大豆磷脂和二硬脂酰磷脂酰乙醇胺‑聚乙二醇2000。本实施例构建的聚合物‑脂质杂合纳米粒能有效改善黄芩苷水溶性差及稳定性弱的理化缺陷,同时实现纳米粒体内长循环、高细胞摄取、磁场定向肿瘤富集多重性能,显著提升黄芩苷肿瘤靶向递送效率,进而有效改善抗肿瘤治疗效果。
Resumen de: CN122849193A
本发明公开了一种仿生细菌囊泡制剂,包括表面修饰有脲酶和叶酸的细菌囊泡和负载于所述细菌囊泡中的活性成分,其中,所述活性成分为级联多酶体系或者治疗性核酸分子。本发明在双歧杆菌囊泡表面修饰脲酶结构,能够催化尿素产生NH3和CO2,NH3中和胃酸防止囊泡降解,而CO2为囊泡的运动提供了微动力。进一步,通过脂质‑叶酸偶联物修饰囊泡,赋予了细菌囊泡靶向小肠的功能。口服给药后,包封在囊泡内的β‑半乳糖苷酶、半乳糖氧化酶和过氧化氢酶发生时空耦合的级联反应,促进乳糖及其中间产物半乳糖和过氧化氢的快速降解,从而对乳糖不耐受产生良好的治疗效果。所述仿生囊泡平台还兼具递送不同mRNA的潜力,为代谢性疾病的治疗提供了一种新方案。
Resumen de: WO2024122721A1
The present application relates to a peptide having a cartilage regeneration effect and uses thereof, and provides a peptide consisting of the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2, a composition for cartilage regeneration comprising the peptide, and a pharmaceutical composition for preventing or treating cartilage diseases, comprising the composition for cartilage regeneration as an active ingredient.
Resumen de: WO2024122723A1
The present application relates to a peptide having a cartilage regeneration effect and uses thereof, and provides a peptide consisting of the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2, a composition for cartilage regeneration comprising the peptide, and a pharmaceutical composition for preventing or treating cartilage diseases, comprising the composition for cartilage regeneration as an active ingredient.
Resumen de: CN122849441A
本发明属于生物医药技术领域,提供了一种负载TRPA1抑制剂的靶向声动力纳米药物及其制备方法。将氯化铁、苯甲酸和TCPP、TRPA1抑制剂混合后反应制备中间体,然后负载GOx并包裹透明质酸获得纳米材料。上述纳米材料可用于治疗过表达CD44受体并且存在TRPA1离子通道介导的钙稳态紊乱或迁移侵袭特征的实体瘤。本发明提供的方法步骤简单、可重复性强,且制备的纳米材料具有良好的生物相容性和安全性。本发明构建的纳米材料将声动力疗法、肿瘤饥饿疗法、铁死亡和离子通道干预有机结合,实现了多重机制的协同增效。在4T1‑Luc原位乳腺癌模型中,该材料联合超声展现出显著的肿瘤生长抑制、肺转移减少的效果。
Resumen de: CN122849159A
本申请涉及生物医药及创新制剂开发技术领域,具体涉及一种眼后段药物递送的脂质体、包含脂质体的滴眼液及其应用。所述脂质体包括脂质体内核和外层短肽修饰层,所述的脂质体内核包括脂质双层膜,所述短肽包括Gly‑Ser。所述脂质体内核中可以稳定包载治疗剂,将其制备为纳米滴眼液。所述的纳米滴眼液在不影响眼表屏障功能的基础上显著提升治疗剂的跨眼后段穿透性,并且显著提升对于眼病的治疗效果。
Resumen de: CN122849004A
本发明公开了一种石墨烯远红外消炎镇痛贴及其制备方法,包括膏体和基布,膏体由膏体基质和分散于其中的功能性微囊组成;功能性微囊包含芯材和壁材,芯材为石墨烯量子点与纳米级远红外陶瓷粉的复合物,壁材为多孔聚乳酸‑羟基乙酸共聚物;膏体基质由包括如下质量份数的组分制备而成:多孔石墨烯气凝胶2~5份、功能性微囊10~25份、热熔胶60~80份、渗透促进剂2~5份、挥发油组分3~10份;多孔石墨烯气凝胶的孔径分布为50~200nm,比表面积为300~600m²/g,且其表面接枝有亲水性羧基和疏水性烷基链,形成两亲性表面结构;将多孔石墨烯气凝胶与功能性微囊复合应用于消炎镇痛贴中,作为高效的导热骨架和远红外辐射增强基体,显著提升热量在膏体层中的传导速率和分布均匀性。
Resumen de: CN122849427A
本发明公开了一种肺炎支原体多价mRNA疫苗及其制备方法和应用,涉及生物医药技术领域。所述疫苗包括编码肺炎支原体抗原的mRNA分子和荷载所述mRNA分子的脂质纳米颗粒;所述肺炎支原体抗原为P1抗原片段、P30抗原片段、P116抗原片段和CARDS抗原片段及其组合;所述P1抗原片段的氨基酸序列如SEQ ID NO:1所示;所述P30抗原片段的氨基酸序列如SEQ ID NO:2所示;所述P116抗原片段的氨基酸序列如SEQ ID NO:3所示;所述CARDS抗原片段的氨基酸序列如SEQ ID NO:4所示。本发明采用非核苷酸修饰的mRNA技术路线,通过序列优化和低dsRNA副产物T7 RNA聚合酶突变体合成策略,在实现高效翻译表达的同时,避免了非预期移码错译蛋白的产生和潜在的脱靶免疫应答,使疫苗更加安全可靠。
Resumen de: CN122854130A
本发明涉及一种仿生型唑类可电离脂质化合物及其制备方法和应用,仿生型唑类可电离脂质化合物结构仿天然磷脂设计,在咪唑环或噻唑环的4位与5位上分别修饰有1,2‑二酰甘油酯,并在咪唑环或噻唑环2位上修饰有不同烷基链长的含氮基团,形成具备四条柔性脂链的四酰基唑类仿生脂质。仿生型唑类可电离脂质化合物与治疗性药物及其他脂质辅料混合,能够制备得到治疗性药物被装载在内的载药脂质纳米颗粒,作为药物递送系统用于脑靶向药物的制备;仿生型唑类可电离脂质化合物具备调控血脑屏障开放‑闭合的功能,能够实现血脑屏障可逆开放;所形成的药物递送系统能够穿越血脑屏障并较好地实现所装载治疗性药物的脑靶向递送。
Resumen de: CN122849189A
本发明属于中药制剂与纳米递送技术领域,具体涉及一种葛根芩连汤果胶‑壳聚糖纳米粒及制备方法和在炎症性肠病相关疾病模型中的应用。采用离子凝胶化法,以壳聚糖为载体,通过带负电的三聚磷酸钠作为交联剂,利用静电相互作用使葛根芩连汤负载于壳聚糖形成纳米粒;再采用果胶对所得纳米粒进行表面包覆,得到葛根芩连汤果胶‑壳聚糖纳米粒。与现有技术相比,本发明工艺温和、步骤简便、重复性好,适用于口服给药及结肠靶向制剂开发。
Resumen de: CN122854573A
本公开涉及靶向递送脂质技术领域,具体涉及一种两性离子聚合物及包含其的脂质组合物和用途。本公开提供的靶向脾的两性离子聚合物具有式(I)所示的结构,可用作RNA靶向递送,能够显著增强mRNA药物对于脾靶向效果。
Resumen de: CN122849186A
本发明公开了一种分阶段实现溶酶体规避与靶向的载药脑部递送载体,其以叶酸修饰的聚合物纳米材料为载药内核,以膜融合脂质体与人脑微血管内皮细胞膜融合形成的仿生杂化膜为包覆层。该载药脑部递送载体跨越血脑屏障时,可通过膜融合机制规避传统溶酶体胞内转运途径,有效避免药物载体在脑微血管内皮细胞内发生溶酶体滞留与降解,保障载药内核高效穿透脑部血管抵达脑实质;随后,载药内核可借助表面特异性配体叶酸精准靶向脑肿瘤细胞,并于其溶酶体内释放药物,一方面有效削弱肿瘤细胞溶酶体的细胞保护效应,另一方面可直接破坏肿瘤细胞溶酶体,引发其功能紊乱和内容物外泄,诱导肿瘤细胞死亡,从多维度显著提升脑肿瘤治疗效果。
Resumen de: CN122849184A
本发明提供了一种负载小分子抗肿瘤药物和光敏剂的功能化仿生纳米粒及其制备方法和应用。该仿生纳米给药系统以TPGS偶联光敏剂Ce6为骨架,包载芫花酯甲(YHC)和黄芪甲苷(AS‑IV),形成YA/Ce6‑TPGS纳米复合物;随后在表面包覆NK细胞膜,构建YA/Ce6‑TPGS@NK功能化仿生靶向递药系统,具有粒径小、载药量和包封率高等特点。系统通过保留NK细胞膜表面的多种蛋白实现对癌细胞的识别与靶向,并降低载体免疫原性,增强循环稳定性,实现精准递送;TPGS‑Ce6载体经光照发挥光动力学杀伤效应,包载的YHC与AS‑IV在肿瘤组织释放,发挥化学抗肿瘤作用,实现化疗与光动力疗法协同抗肿瘤作用。体内外实验表明,其具有显著的抗肿瘤活性和良好生物相容性,并呈现良好的肿瘤靶向性以及潜在的逆转耐药能力。
Nº publicación: CN122854163A 02/10/2026
Solicitante:
华中农业大学
Resumen de: CN122854163A
本发明涉及一种基于香豆素结构的新型有机声敏剂DBCA及其仿生纳米颗粒在肿瘤声动力治疗中的应用。本发明所述声敏剂具有结构简单、原料易得、合成路线短、成本低等优势,在超声作用下能够高效产生ROS,实现对肿瘤细胞的杀伤作用,并具有极低光毒性和良好生物安全性。本发明进一步提供以DSPE‑PEG2000将DBCA包裹形成的纳米颗粒DBCA@PEG,随后利用放疗诱导的肿瘤细胞膜包覆并可联合免疫佐剂获得仿生纳米颗粒DBCA@RM。该仿生结构赋予纳米颗粒同源靶向性,延长肿瘤内驻留时间,同时带有肿瘤相关抗原和固有免疫刺激特性,有助于增强声动力治疗及免疫激活效应。本发明的纳米制剂可应用于肿瘤精准治疗、声动力治疗等领域,具有良好的应用前景。